Skip to main content

Advertisement

Table 4 Statistical analysis: CCND1, CCNE1, CDKN2A associations with clinico-pathological features and other gene alterations.

From: Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma

CDKN2A CDKN2A presence of homozygous deletion n (%) CDKN2A absence of homozygous deletion n (%) p
Age   62 62,6 NS
Gender Women 6 (12) 44 (88) 0,157
  Men 2 (4) 46 (96)  
Histology ADC 7 (10) 61 (90) 0,483
  LCC 0 (0) 6 (100)  
  SCC 1 (4) 23 (96)  
Tobacco Never-smoker 5 (20) 20 (80) 0,012
  Smoker 3 (4) 70 (96)  
  Mutated 5 (33) 10 (67)  
EGFR Non-mutated 3 (4) 80 (96) 0,002
  Mutated 1 (5) 19 (95)  
KRAS Non-mutated 7 (9) 71 (91) 0,563
  Mutated 1 (14) 6 (86)  
STK11 Non-mutated 7 (8) 84 (92) 0,46
  Mutated 3 (7) 40 (93)  
TP53 Non-mutated 5 (9) 50 (91) 0,704
AKT-mTOR activation* Yes 7 (29) 17 (71) <0,001
  No 1 (1) 73 (99)  
CCND1 Amplification n (%) No amplification n (%) P
Age   61,8 63 NS
Gender Women 5 (10) 45 (90) 0,331
  Men 8 (17) 40 (83)  
Histology ADC 6 (9) 62 (91) 0,079
  LCC 2 (33) 4 (67)  
  SCC 5 (21) 19 (71)  
Tobacco Never-smoker 0 25 (100) 0,023
  Smoker 13 (18) 60 (82)  
EGFR Mutated 1 (7) 14 (93) 0,331
  Non-mutated 12 (14) 71 (86)  
KRAS Mutated 2 (10) 18 (90) 0,629
  Non-mutated 11 (14) 67 (86)  
STK11 Mutated 1 (1) 6 (99) 0,934
  Non-mutated 12 (13) 79 (87)  
TP53 Mutated 9 (21) 34 (79) 0,048
  Non-mutated 4 (7) 51 (83)  
AKT-mTOR activation* Yes 2 (8) 22 (92) 0,412
  No 11 (15) 63 (85)  
CCNE1 Amplification n (%) No-amplification n (%) P
Age   67 62,5 NS
Gender Women 2 (4) 47 (96) 0,371
  Men 4 (8) 45 (92)  
Histology ADC 2 (3) 66 (97) 0,099
  LCC 1 (1) 5 (99)  
  SCC 3 (13) 21 (87)  
Tobacco Never-smoker 1 (1) 24 (99) 0,518
  Smoker 5 (17) 68 (83)  
EGFR Mutated 1 (1) 14 (99) 0,924
  Non-mutated 5 (7) 78 (93)  
KRAS Mutated 1 (1) 19 (99) 0,814
  Non-mutated 5 (6) 73 (94)  
STK11 Mutated 0 7 (100) 0,483
  Non-mutated 6 (7) 85 (93)  
TP53 Mutated 6 (15) 37 (85) 0,006
  Non-mutated 0 55 (100)  
AKT-mTOR activation* Yes 2 (8) 22 (82) 0,603
  No 4 (5) 70 (85)  
  1. In this work we called PI3K-AKT-mTOR activated tumors, tumors with either EGFR, PIK3CA, ERBB2 or STK11 mutation*.